BioSpecifics Technologies Corp. (NASDAQ: BSTC) Starts Presentation at NobleCon13
BioSpecifics Technologies (NASDAQ: BSTC) is a biopharmaceutical company that engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. BioSpecifics is also involved in the development of other clinical indications for which collagenase…